All Stories

  1. Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging

    Article • Drug Design Development and Therapy, August 2015, Dove Medical Press

    Dr Josep M Llibre

  2. Perfil de resistencias y barrera genética de dolutegravir

    Article • Enfermedades Infecciosas y Microbiología Clínica, March 2015, Elsevier

    Dr Josep M Llibre

  3. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

    Article • Enfermedades Infecciosas y Microbiología Clínica, March 2015, Elsevier

    Dr Josep M Llibre

  4. Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals

    Article • PLoS ONE, December 2014, PLOS

    Dr Josep M Llibre

  5. Hidden costs of HIV treatment in Spain: inefficiency of the antiretroviral drug packaging

    Article • Journal of the International AIDS Society, November 2014, Wiley

    Dr Josep M Llibre

  6. Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction

    Article • Enfermedades Infecciosas y Microbiología Clínica, November 2014, Elsevier

    Dr Josep M Llibre

  7. Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study

    Article • Journal of the International AIDS Society, November 2014, Wiley

    Dr Josep M Llibre

  8. Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression

    Article • Journal of the International AIDS Society, November 2014, Wiley

    Dr Josep M Llibre

  9. Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance

    Article • HIV Medicine, March 2014, Wiley

    Dr Josep M Llibre

  10. Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

    Article • PLoS ONE, January 2014, PLOS

    Dr Josep M Llibre

  11. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

    Article • AIDS, January 2014, Wolters Kluwer Health

    Dr Josep M Llibre

  12. Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir

    Article • Antiviral Therapy, January 2014, International Medical Press

    Dr Josep M Llibre

  13. Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Dr Josep M Llibre

  14. Effectiveness of efavirenz compared with ritonavir-boosted protease inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml

    Article • Antiviral Therapy, January 2014, International Medical Press

    Dr Josep M Llibre

  15. Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2013 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana

    Article • Enfermedades Infecciosas y Microbiología Clínica, November 2013, Elsevier

    Dr Josep M Llibre

  16. Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory Study

    Article • PLoS ONE, July 2013, PLOS

    Dr Josep M Llibre

  17. Perfil de resistencia de rilpivirina

    Article • Enfermedades Infecciosas y Microbiología Clínica, June 2013, Elsevier

    Dr Josep M Llibre

  18. Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, June 2013, Wolters Kluwer Health

    Dr Josep M Llibre

  19. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries

    Article • Scandinavian Journal of Infectious Diseases, April 2013, Taylor & Francis

    Dr Josep M Llibre

  20. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    Article • AIDS, January 2013, Wolters Kluwer Health

    Dr Josep M Llibre, Dr. Vicente Soriano

  21. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

    Article • Atherosclerosis, November 2012, Elsevier

    Dr Josep M Llibre

  22. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

    Article • AIDS, November 2012, Wolters Kluwer Health

    Dr Josep M Llibre

  23. Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort

    Article • AIDS, October 2012, Wolters Kluwer Health

    Dr Josep M Llibre

  24. Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH)

    Article • Enfermedades Infecciosas y Microbiología Clínica, June 2012, Elsevier

    Dr Josep M Llibre

  25. Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile

    Article • PLoS ONE, May 2012, PLOS

    Dr Josep M Llibre

  26. Effectiveness of Antiretroviral Therapy in HIV-1-Infected Active Drug Users Attended in a Drug Abuse Outpatient Treatment Facility Providing a Multidisciplinary Care Strategy

    Article • Current HIV Research, May 2012, Bentham Science Publishers

    Dr Josep M Llibre

  27. Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice

    Article • AIDS Research and Human Retroviruses, February 2012, Mary Ann Liebert Inc

    Dr Josep M Llibre

  28. Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial

    Article • Enfermedades Infecciosas y Microbiología Clínica, December 2011, Elsevier

    Dr Josep M Llibre

  29. Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART

    Article • PLoS Pathogens, October 2011, PLOS

    Dr Josep M Llibre

  30. The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, October 2011, Wolters Kluwer Health

    Dr Josep M Llibre

  31. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy

    Article • AIDS, September 2011, Wolters Kluwer Health

    Dr Josep M Llibre

  32. Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients

    Article • AIDS Research and Human Retroviruses, July 2011, Mary Ann Liebert Inc

    Dr Josep M Llibre

  33. Encefalitis con múltiples lesiones cerebrales ocupantes de espacio en un paciente con infección por el virus de la inmunodeficiencia humana tipo 1

    Article • Enfermedades Infecciosas y Microbiología Clínica, March 2011, Elsevier

    Dr Josep M Llibre

  34. Respuesta completa al tratamiento con doxiciclina en pacientes con infección por VIH-1 con proctitis por linfogranuloma venéreo

    Article • Enfermedades Infecciosas y Microbiología Clínica, February 2011, Elsevier

    Dr Josep M Llibre

  35. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study

    Article • Antiviral Therapy, January 2011, International Medical Press

    Dr Josep M Llibre

  36. Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients

    Article • Antiviral Therapy, January 2011, International Medical Press

    Dr Josep M Llibre

  37. El papel de las combinaciones de antirretrovirales a dosis fijas en el tratamiento de la infección por VIH-1

    Article • Enfermedades Infecciosas y Microbiología Clínica, November 2010, Elsevier

    Dr Josep M Llibre

  38. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

    Article • AIDS, July 2010, Wolters Kluwer Health

    Dr Josep M Llibre

  39. Clinical Implications of Genotypic Resistance to the Newer Antiretroviral Drugs in HIV‐1–Infected Patients with Virological Failure

    Article • Clinical Infectious Diseases, March 2010, Oxford University Press (OUP)

    Dr Josep M Llibre

  40. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

    Article • Nature Medicine, March 2010, Springer Science + Business Media

    Dr Josep M Llibre

  41. Effect of Nevirapine on the Steady-State Trough Concentrations of Atazanavir in HIV-Infected Patients Receiving Atazanavir/Ritonavir

    Article • Therapeutic Drug Monitoring, February 2010, Wolters Kluwer Health

    Dr Josep M Llibre

  42. Do we need genotypic weighted resistance scores for antiretrovirals? The curious case of tipranavir

    Article • Antiviral Therapy, January 2010, International Medical Press

    Dr Josep M Llibre

  43. Etravirina: barrera genética y desarrollo de resistencias

    Article • Enfermedades Infecciosas y Microbiología Clínica, December 2009, Elsevier

    Dr Josep M Llibre

  44. Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression

    Article • HIV Clinical Trials, December 2009, Taylor & Francis

    Dr Josep M Llibre

  45. Lymphogranuloma Venerium Proctitis in the Setting of HIV: A Case Report and Differential Diagnosis

    Article • AIDS Patient Care and STDs, July 2009, Mary Ann Liebert Inc

    Dr Josep M Llibre

  46. The Changing Face of HIV/AIDS in Treated Patients

    Article • Current HIV Research, July 2009, Bentham Science Publishers

    Dr Josep M Llibre

  47. A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, July 2009, Wolters Kluwer Health

    Dr Josep M Llibre

  48. How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?

    Article • AIDS Research and Human Retroviruses, June 2009, Mary Ann Liebert Inc

    Dr Josep M Llibre

  49. Unboosted Atazanavir Plus Co-formulated Lamivudine/Abacavir as a Ritonavir-Sparing Simplification Strategy in Routine Clinical Practice

    Article • HIV Clinical Trials, June 2009, Taylor & Francis

    Dr Josep M Llibre

  50. Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, May 2009, Wolters Kluwer Health

    Dr Josep M Llibre

  51. Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2009, Wolters Kluwer Health

    Dr Josep M Llibre

  52. Potencial de los inhibidores de la integrasa para deplecionar los reservorios o para impedir que se rellenen

    Article • Enfermedades Infecciosas y Microbiología Clínica, November 2008, Elsevier

    Dr Josep M Llibre

  53. Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, September 2008, Wolters Kluwer Health

    Dr Josep M Llibre

  54. Genotypic Resistance in HIV-Infected Naive Patients Receiving Abacavir Plus Lamivudine and Efavirenz

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, October 2007, Wolters Kluwer Health

    Dr Josep M Llibre

  55. Costes de la toxicidad asociada a los análogos de nucleósidos inhibidores de la transcriptasa inversa en pacientes con infección por el VIH-1

    Article • Enfermedades Infecciosas y Microbiología Clínica, February 2007, Elsevier

    Dr Josep M Llibre

  56. Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, February 2007, Wolters Kluwer Health

    Dr Josep M Llibre

  57. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients

    Article • AIDS, January 2007, Wolters Kluwer Health

    Dr Josep M Llibre

  58. Análisis de minimización de costes de diferentes combinaciones de inhibidores de la transcriptasa inversa análogos de nucleósidos asociados a acontecimientos adversos en pacientes infectados por el VIH-1

    Article • PharmacoEconomics Spanish Research Articles, January 2007, Springer Science + Business Media

    Dr Josep M Llibre

  59. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

    Article • AIDS, June 2006, Wolters Kluwer Health

    Dr Josep M Llibre

  60. Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients

    Article • AIDS Research and Human Retroviruses, April 2006, Mary Ann Liebert Inc

    Dr Josep M Llibre

  61. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir

    Article • AIDS, September 2005, Wolters Kluwer Health

    Dr Josep M Llibre

  62. Failure of Cetirizine to Prevent Nevirapine-Associated Rash

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, October 2004, Wolters Kluwer Health

    Dr Josep M Llibre

  63. Celulitis cervical y piomiositis en paciente diabético

    Article • Revista Clínica Española, October 2004, Elsevier

    Dr Josep M Llibre

  64. Improvement of dyslipidemia in patients switching from stavudine to tenofovir

    Article • AIDS, July 2004, Wolters Kluwer Health

    Dr Josep M Llibre

  65. Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

    Article • New England Journal of Medicine, September 2003, New England Journal of Medicine (NEJM/MMS)

    Dr Josep M Llibre

  66. Severe Interaction between Ritonavir and Acenocoumarol

    Article • Annals of Pharmacotherapy, April 2002, SAGE Publications

    Dr Josep M Llibre

  67. Severe Interaction Between Ritonavir and Acenocoumarol

    Article • Annals of Pharmacotherapy, April 2002, SAGE Publications

    Dr Josep M Llibre

  68. La imagen de la semana

    Article • Medicina Clínica, January 2000, Elsevier

    Dr Josep M Llibre

  69. Bronchiolitis Obliterans Organizing Pneumonia Associated with Acute Mycoplasma pneumoniae Infection

    Article • Clinical Infectious Diseases, December 1997, Oxford University Press (OUP)

    Dr Josep M Llibre

  70. Efficacy and safety of α-interferon treatment for chronic hepatitis C in HIV-infected patients

    Article • Journal of Infection, July 1995, Elsevier

    Dr Josep M Llibre, Dr. Vicente Soriano

  71. High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain

    Article • Journal of Hepatology, May 1995, Elsevier

    Dr Josep M Llibre, Dr. Vicente Soriano

  72. Antimicrobial prophylaxis for dental extractions after splenectomy

    Article • The Lancet, June 1991, Elsevier

    Dr Josep M Llibre

  73. Epidemic Kaposiʼs sarcoma in Spanish AIDS patients

    Article • AIDS, December 1989, Wolters Kluwer Health

    Dr Josep M Llibre

  74. BLASTOCYSTIS HOMINIS CHRONIC DIARRHOEA IN AIDS PATIENTS

    Article • The Lancet, January 1989, Elsevier

    Dr Josep M Llibre